Total Payments
$583,963
2024 Payments
$31,634
Companies
26
Transactions
156
Medicare Patients
674
Medicare Billing
$96,244
Payment Breakdown by Category
Research$400,434 (68.6%)
Consulting$108,434 (18.6%)
Other$45,453 (7.8%)
Travel$27,481 (4.7%)
Food & Beverage$2,144 (0.4%)
Education$18.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $400,434 | 28 | 68.6% |
| Consulting Fee | $108,434 | 50 | 18.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,419 | 5 | 5.0% |
| Travel and Lodging | $27,481 | 36 | 4.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,234 | 3 | 2.3% |
| Honoraria | $2,800 | 2 | 0.5% |
| Food and Beverage | $2,144 | 31 | 0.4% |
| Education | $18.09 | 1 | 0.0% |
Payments by Type
Research
$400,434
28 transactions
General
$183,530
128 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $384,324 | 3 | $0 (2019) |
| Merck Sharp & Dohme LLC | $56,022 | 31 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $37,924 | 12 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $13,728 | 9 | $0 (2021) |
| Novocure Inc. | $13,700 | 9 | $0 (2023) |
| SERVIER AFFAIRES MEDICALES | $10,696 | 15 | $0 (2023) |
| Servier BioInnovation | $8,573 | 11 | $0 (2024) |
| AbbVie, Inc. | $7,627 | 14 | $0 (2017) |
| GlaxoSmithKline, LLC. | $5,800 | 3 | $0 (2023) |
| Blue Earth Diagnostics Limited | $5,775 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,634 | 20 | SERVIER PHARMACEUTICALS LLC ($19,406) |
| 2023 | $16,964 | 22 | SERVIER AFFAIRES MEDICALES ($10,696) |
| 2022 | $9,038 | 5 | SERVIER PHARMACEUTICALS LLC ($5,280) |
| 2021 | $38,169 | 19 | Servier Pharmaceuticals LLC ($13,239) |
| 2020 | $23,690 | 10 | Merck Sharp & Dohme Corporation ($8,150) |
| 2019 | $410,120 | 33 | Eli Lilly and Company ($382,500) |
| 2018 | $25,488 | 19 | Merck Sharp & Dohme Corporation ($14,973) |
| 2017 | $28,861 | 28 | Merck Sharp & Dohme Corporation ($14,332) |
All Payment Transactions
156 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $160.62 | General |
| 11/20/2024 | Servier BioInnovation | — | Food and Beverage | In-kind items and services | $196.85 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $4,150.00 | General |
| 10/30/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $122.38 | General |
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $2,791.11 | Research |
| Study: STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,397.92 | Research |
| Study: STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,018.33 | Research |
| Study: Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | ||||||
| 07/10/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $2,905.00 | General |
| 07/03/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 06/27/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $711.67 | Research |
| Study: STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | ||||||
| 06/27/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $533.75 | Research |
| Study: STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | ||||||
| 06/27/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $355.83 | Research |
| Study: Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | ||||||
| 06/26/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $6,120.00 | General |
| 06/26/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $3,060.00 | General |
| 05/22/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $63.85 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 04/25/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 03/08/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $2,490.00 | General |
| 03/08/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | Cash or cash equivalent | $558.17 | General |
| 12/07/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $445.73 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $469.66 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $469.66 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $454.00 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 10/22/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $664.72 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF ABEMACICLIB FOR PATIENTS WITH RETINOBLASTOMA-POSITIVE, TRIPLE NEGATIVE METASTATIC BREAST CANCER | Eli Lilly and Company | $382,500 | 1 |
| STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | SERVIER AFFAIRES MEDICALES | $7,096 | 14 |
| STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | Servier BioInnovation | $3,503 | 2 |
| Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | Servier BioInnovation | $2,941 | 6 |
| STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | Servier BioInnovation | $1,932 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,184 | 1 |
| CAAA601A52101 | Novartis Pharma AG | $766.50 | 1 |
| GBM Study | Novartis Pharma AG | $511.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 130 | 201 | $112,564 | $20,503 |
| 2022 | 6 | 169 | 250 | $140,442 | $26,320 |
| 2021 | 6 | 149 | 224 | $110,099 | $24,014 |
| 2020 | 8 | 226 | 301 | $106,640 | $25,407 |
Total Patients
674
Total Services
976
Medicare Billing
$96,244
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 78 | $56,664 | $9,504 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 43 | 55 | $22,490 | $4,418 | 19.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $17,791 | $3,093 | 17.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 31 | $8,618 | $2,094 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 17 | $7,001 | $1,395 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 50 | 99 | $69,584 | $12,261 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 87 | $34,515 | $6,810 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $17,300 | $3,168 | 18.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $11,265 | $2,418 | 21.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 15 | $4,170 | $914.26 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 14 | $3,608 | $748.24 | 20.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 78 | $46,796 | $9,380 | 20.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 73 | $24,487 | $6,025 | 24.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 30 | 30 | $22,257 | $4,806 | 21.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $8,261 | $1,912 | 23.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 18 | $5,004 | $1,123 | 22.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 14 | $3,294 | $767.78 | 23.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 43 | 67 | $31,967 | $6,033 | 18.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 85 | $22,443 | $5,527 | 24.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 25 | 26 | $17,272 | $4,242 | 24.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $15,594 | $4,019 | 25.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 35 | 44 | $9,334 | $3,006 | 32.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 17 | $4,114 | $1,080 | 26.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 23 | $4,194 | $1,000 | 23.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 11 | 12 | $1,722 | $498.32 | 28.9% |
About Dr. Patrick Wen, MD
Dr. Patrick Wen, MD is a Neurology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1053393496.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Wen, MD has received a total of $583,963 in payments from pharmaceutical and medical device companies, with $31,634 received in 2024. These payments were reported across 156 transactions from 26 companies. The most common payment nature is "" ($400,434).
As a Medicare-enrolled provider, Wen has provided services to 674 Medicare beneficiaries, totaling 976 services with total Medicare billing of $96,244. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Boston, MA
- Active Since 11/18/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1053393496
Products in Payments
- TIBSOVO (Drug) $19,339
- Axumin (Drug) $5,775
- Lonsurf (Drug) $5,403
- Nerlynx (Drug) $3,231
- ILLUCCIX (Drug) $3,064
- Stivarga (Drug) $2,528
- Oncology (Device) $1,800
- TEMODAR (Drug) $1,719
- TABRECTA (Drug) $1,533
- LENVIMA (Drug) $1,500
- TAGRISSO (Drug) $1,500
- Avastin (Biological) $1,406
- LUTATHERA (Drug) $1,278
- TAFINLAR (Drug) $1,184
- Optune (Device) $1,000
- IMFINZI (Drug) $974.25
- QSYMIA (Drug) $800.00
- WELIREG (Drug) $18.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Boston
Christopher Wright, Md, MD
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Alfred Sandrock, Md Phd, MD PHD
Neurology — Payments: $1.2M
Neurology $1.2M
Thomas Scammell, M.d, M.D
Neurology — Payments: $598,925
Neurology $598,925
Dr. Michael Levy, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $519,354
Neurology $519,354
Roy Freeman, M.d, M.D
Neurology — Payments: $489,143
Neurology $489,143
Dr. Sheena Chew, Md, MD
Neurology — Payments: $328,987
Neurology $328,987